The Global Market for PAH Therapeutics is Projected to Reach US$6.1 Billion by 2022
High Unmet Treatment Needs & Discovery of New
Disease Pathways for the Development of More Effective Drugs Drive the Pulmonary
Arterial Hypertension Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.
GIA
launches comprehensive analysis of industry segments, trends, growth drivers,
market share, size and demand forecasts on the global Pulmonary Arterial
Hypertension (PAH) Therapeutics market. The global market for PAH Therapeutics is projected to
reach US$6.1 billion by 2022, driven
by improving diagnosis rates and development of novel drugs as a result of progressive
and measurable improvements in understanding and management of the disease from
pathology, physiology and pharmacology perspectives.
Pulmonary Arterial
Hypertension (PAH) is characterized by abnormal high blood pressure in the
pulmonary arteries that puts strain on the heart and eventually results in
cardiac failure. Incidence of the disease is rare, affecting about 15-50 in a
million people and increases with age. The symptoms of PAH are non-specific,
similar to those of other heart and lung conditions, and range from fatigue and
mild breathlessness during normal daily activity to right heart failure and
limited exercise ability. Medication for PAH
comprises vasodilators that aid in relaxing constricted pulmonary blood
vessels, reducing symptoms and slowing the disease progression. The impact on market
growth due to the loss of market exclusivity of major drugs such as Tracleer, is
counterbalanced by the development and launch of innovative safer and efficient
new drugs with low side effects. The market is characterized by intense competition
among existing players and increase in research and development activities. In
addition, adoption of combination therapy involving various drug combinations
is expected to benefit market growth. Pediatric pulmonary arterial hypertension
(PAH) stands out as a lucrative market opportunity.
Major drugs prescribed specifically for PAH fall
under the broad categories - prostacyclin and its analogs, endothelin receptor
antagonists (ERAs), phosphodiesterase type 5 (PDE-5) inhibitors, and Soluble
Guanylate Cyclase (sGC) Stimulators. While Endothelin Receptor Antagonist (ERA)
currently dominate the PAH therapeutics market, newer forms of administration
of prostacyclin and its analogs are forecast to report stronger growth over the
analysis period. Oral therapies form the
most preferred mode of administration for treatment of PAH as they are
relatively easier to administer and more effective than other routes of
administration such as intravenous or inhaled.
As stated by the new
market research report on Pulmonary Arterial Hypertension (PAH) Therapeutics, the
United States represents the largest market worldwide. Asia-Pacific ranks as the
fastest growing market, with a CAGR of 7.7% over the analysis period, led by
factors such as large
population and healthcare burden; improving disease awareness; rising per
capita healthcare spending as a result of growing income and affluence; government
policy led development of healthcare infrastructure; and rise in risk factors
for PAH such as use of methamphetamine and cocaine, high incidence of diseases
like lupus, scleroderma, cirrhosis of the liver, HIV infection, and portal hypertension.
Major
players covered in the report include Actelion Pharmaceuticals
Ltd., Bayer AG, Gilead Sciences, Inc., Pfizer Inc., United
Therapeutics Corporation and Lung Biotechnology PBC.
The
research report titled "Pulmonary Arterial Hypertension (PAH) Therapeutics: A
Global Strategic Business Report"
announced by Global Industry Analysts Inc., provides a comprehensive review of
market trends, growth drivers, mergers and acquisitions, and other strategic
industry activities of major companies worldwide. The report provides market
estimates and projections for geographic markets, such as the US, Canada, Japan,
Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, Latin
America, and Rest of World. Analysis is further provided for the period
2009-2018 by dug brands / categories including by Drugs - Endothelin Receptor
Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin
and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag,
Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio
(Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat).
Comments
Post a Comment